Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)

View Full Paper
Ask AI
Bookmark
Share

Authors

VPVáclava PolívkováŠHŠtěpán HrabovskýZKZdeněk Kořı́stek

Discussion

Loading...

Member takes

Overview

Observational analysis reports improved survival in adults with Philadelphia-negative B-ALL, suggesting targeted therapy's role in treatment response.

Key Points

  • Overall survival reached 69%, with notable outcomes tied to molecular subtypes and treatment responses.
  • Among patients with DUX4-rearranged B-ALL, an impressive 100% overall survival indicates a unique response pattern.
  • Incorporating genomic testing like whole-exome sequencing enhances understanding of molecular subtypes in B-ALL treatment.
  • Integration of advanced testing into clinical protocols may significantly improve personalized therapy outcomes.

Cite This Study

Polívková et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de7ahttps://doi.org/10.1182/blood-2025-1587
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial2025 · 2 citations
  2. 2Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia2025
  3. 3Multi-omic analysis of early minimal residual disease identifies functional and transcriptomic signatures of treatment resistance in pediatric B-cell acute lymphoblastic leukemia2025
  4. 4Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  5. 5Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma2025